Compare GSK plc (GSK) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? GSK plc trades at $50.3 (market cap $102.60B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.28. The key difference: GSK plc pays a 3.57% dividend while iShares Broad USD Investment Grade Corporate Bond pays none, and GSK plc is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| GSK | USIG | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $52.69 |
52-Week Low | $38.22 | $50.18 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
USIG is trading at $50.32, up 0.27% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent corporate actions include dividend payments, with the latest being $0.21 per share. A key development is AM Best's affirmation of credit ratings for USIG subsidiaries following a transaction with Tiptree Inc., as reported by Business Wire on July 30, 2026.
The outlook is cautious due to bearish technical indicators and limited fundamental data availability. Investment opportunities may arise from stable dividend payments and institutional interest, such as Bank of New York Mellon Corp increasing its stake. Risks include reliance on external financial data and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
